Madison’s Exact Sciences Corp., a provider of cancer screening and diagnostic tests, announced in a press release today that it has filed a lawsuit against Geneoscopy Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or offering for sale Geneoscopy’s ColoSense product or otherwise infringing on U.S. Patent No. 11,634,781 (“the ’781 Patent”) held by Exact Sciences.
Exact Sciences utilizes the patented ’781 technology in its Cologuard stool DNA-based colorectal cancer screening test. After receiving a cease-and-desist letter from Exact Sciences regarding its patent infringement, Geneoscopy requested a reexamination of the ’781 patent by the United States Patent and Trademark Office in May. Upon completion of the reexamination in October, the USPTO rejected Geneoscopy’s challenge, confirming the patentability of all claims of the ’781 patent for Exact Sciences.
